A phase II randomized controlled trial of three exercise delivery methods in men with prostate cancer on androgen deprivation therapy.

Shabbir M H Alibhai, Daniel Santa Mina, Paul Ritvo, George Tomlinson, Catherine Sabiston, Murray Krahn, Sara Durbano, Andrew Matthew, Padraig Warde, Meagan O'Neill, Narhari Timilshina, Roanne Segal, Nicole Culos-Reed

Journal: BMC cancer 2019;19(1):2

PMID: 30606137

Plain Language Summary

plain language summary logo

Most men diagnosed with prostate cancer receive androgen deprivation therapy (ADT) and they commonly experience adverse side effects. Exercise is one of the most effective interventions to counter ADT side effects. The main aim of this study was to determine the feasibility of conducting a large multi-centre non-inferiority RCT of three exercise delivery models in men with prostate cancer on ADT. The study is a randomized phase II non-inferiority trial recruited 59 patients who were diagnosed with prostate cancer at any stage. The study compared 1:1, site-based personal training with two less-resource-intense approaches: group, site-training and individual home-based training. Results indicate that exercise adherence, as measured through attendance, was high for supervised sessions but under 50% by self-report and accelerometery. There was no difference between the three groups in terms of satisfaction. Authors conclude that both group, site-training and individual home-based training interventions in men with prostate cancer on ADT appeared to be similar to 1:1, site-based personal training for multiple efficacy outcomes.

Abstract

BACKGROUND

Existing evidence demonstrates that 1:1 personal training (PT) improves many adverse effects of androgen deprivation therapy (ADT). Whether less resource-intensive exercise delivery models are as effective remains to be established. We determined the feasibility of conducting a multi-center non-inferiority randomized controlled trial comparing PT with supervised group (GROUP) and home-based (HOME) exercise programs, and obtained preliminary efficacy estimates for GROUP and HOME compared to PT on quality of life (QOL) and physical fitness.

METHODS

Men with prostate cancer on ADT were recruited from one of two experienced Canadian centres and randomized 1:1:1 to PT, GROUP, or HOME. Randomization was stratified by length of ADT use and site. Participants completed moderate intensity aerobic and resistance exercises 4-5 days per week for 6 months with a target 150 min per week of exercise. Exercise prescriptions were individualized and progressed throughout the trial. Feasibility endpoints included recruitment, retention, adherence, and participant satisfaction. The efficacy endpoints QOL, fatigue, and fitness (VO2 peak, grip strength, and timed chair stands) in GROUP and HOME were compared for non-inferiority to PT. Descriptive analyses were used for feasibility endpoints. Between-group differences for efficacy endpoints were examined using Bayesian linear mixed effects models.

RESULTS

Fifty-nine participants (mean age 69.9 years) were enrolled. The recruitment rate was 25.4% and recruitment was slower than projected. Retention was 71.2%. Exercise adherence as measured through attendance was high for supervised sessions but under 50% by self-report and accelerometry. Satisfaction was high and there was no difference in this measure between all three groups. Between-group differences (comparing both GROUP and HOME to PT) were smaller than the minimum clinically important difference on most measures of QOL, fatigue, and fitness. However, two of six outcomes for GROUP and four of six outcomes for HOME had a > 20% probability of being inferior for GROUP.

CONCLUSIONS

Feasibility endpoints were generally met. Both GROUP and HOME interventions in men with PC on ADT appeared to be similar to PT for multiple efficacy outcomes, although conclusions are limited by a small sample size and cost considerations have not been incorporated. Efforts need to be targeted to improving recruitment and adherence. A larger trial is warranted.

TRIAL REGISTRATION

ClinicalTrials.gov: NCT02046837 . Date of registration: January 20, 2014.

Address: University Health Network, University of Toronto, Toronto, ON, M5G 2C4, Canada. [email protected].; Toronto General Hospital, 200 Elizabeth St Room EN14-214, Toronto, Ontario, M5G 2C4, Canada. [email protected].; University Health Network, University of Toronto, Toronto, ON, M5G 2C4, Canada.; Cancer Care Ontario, York University, Toronto, ON, M3J 1P3, Canada.; Cancer Care Ontario, York University, Toronto, ON, M3J 1P3, Canada.; University of Toronto, Toronto, ON, M5S 2J7, Canada.; University Health Network, University of Toronto, Toronto, ON, M5G 2C4, Canada.; University Health Network, University of Toronto, Toronto, ON, M5G 2C4, Canada.; Cancer Care Ontario, York University, Toronto, ON, M3J 1P3, Canada.; University of Toronto, Toronto, ON, M5S 2J7, Canada.; The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON, K1N 6N5, Canada.; University of Calgary, Calgary, AB, T2N 1N4, Canada.

Patient Centred Factor

Clinical Imbalances

Modifiable Lifestyle Factors

Jadad Score

Allocation Concealment

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.